Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab in Pediatric Plaque Psoriasis (Extension)
NCT04862286Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2021
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of risankizumab in plaque psoriasis, sponsored by AbbVie Inc.. Started Jul 2021; status: active, not recruiting.
02
Drugs
risankizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04862286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04862286.